nootropic agents

Summary

Summary: Drugs used to specifically facilitate learning or memory, particularly to prevent the cognitive deficits associated with dementias. These drugs act by a variety of mechanisms. While no potent nootropic drugs have yet been accepted for general use, several are being actively investigated.

Top Publications

  1. ncbi [Anticholinesterase agents in Alzheimer's disease]
    M Ventura
    , Bruxelles
    Rev Med Brux 22:A387-93. 2001
  2. ncbi Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study
    Tatjana Klinger
    Staedt Klinikum St Georg, Verbund Gemeindenahe Psychiatrie West Suedwest, Leipzig, Germany
    Curr Med Res Opin 21:723-32. 2005
  3. ncbi Reaching the population with dementia drugs: what are the challenges?
    Fiona E Matthews
    MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK
    Int J Geriatr Psychiatry 22:627-31. 2007
  4. ncbi Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase
    Anthony L Albiston
    Howard Florey Institute, University of Melbourne, Parkville, VIC 3010, Australia
    FASEB J 22:4209-17. 2008
  5. ncbi Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany
    A G Franke
    Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany
    Pharmacopsychiatry 44:60-6. 2011
  6. ncbi Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany
    A G Franke
    Department of Psychiatry and Psychotherapy, University Medical Centre Mainz, Mainz, Germany
    Pharmacopsychiatry 44:331-8. 2011
  7. ncbi Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice
    Julie Vignisse
    School for Mental Health and Neuroscience, Department of Neuroscience, Maastricht University, Universiteitssingel 50, NL 6229 ER Maastricht, The Netherlands
    Prog Neuropsychopharmacol Biol Psychiatry 35:510-22. 2011
  8. pmc Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity
    Daniel M Fass
    Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA
    Neuropharmacology 64:81-96. 2013
  9. ncbi Citicoline in vascular cognitive impairment and vascular dementia after stroke
    Jose Alvarez-Sabin
    Neurovascular Unit, Department of Neurology, Universitat Autonoma de Barcelona, Hospital Vall d Hebron, Barcelona, Spain
    Stroke 42:S40-3. 2011
  10. ncbi Neuroprotection and recovery: recent data at the bench on citicoline
    Olivia Hurtado
    Unidad de Investigación Neurovascular, Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Avda Complutense s n, 28040 Madrid, Spain
    Stroke 42:S33-5. 2011

Research Grants

  1. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
  2. Evaluation of Antioxidant Suppl in Focal CNS Ischemia
    Wayne Clark; Fiscal Year: 2003
  3. Cocaine Withdrawal and Pharmacotherapy Response
    Mehmet Sofuoglu; Fiscal Year: 2010
  4. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2006
  5. GABA Medications for Tobacco Addiction
    Mehmet Sofuoglu; Fiscal Year: 2009
  6. Kinase Inhibitors against Neurodegeneration
    Gary Lynch; Fiscal Year: 2004
  7. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
  8. Integrin and LTP Consolidation
    Gary Lynch; Fiscal Year: 2003
  9. Diethanolamine, brain development and adult memory
    Steven Zeisel; Fiscal Year: 2006
  10. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006

Detail Information

Publications234 found, 100 shown here

  1. ncbi [Anticholinesterase agents in Alzheimer's disease]
    M Ventura
    , Bruxelles
    Rev Med Brux 22:A387-93. 2001
    ..Nevertheless a simplification of the prescriptions is justified, to the detriment of drugs without any proven activity...
  2. ncbi Effect of donepezil in patients with Alzheimer's disease previously untreated or treated with memantine or nootropic agents in Germany: an observational study
    Tatjana Klinger
    Staedt Klinikum St Georg, Verbund Gemeindenahe Psychiatrie West Suedwest, Leipzig, Germany
    Curr Med Res Opin 21:723-32. 2005
    ..A treatment-naive population was included as a comparator...
  3. ncbi Reaching the population with dementia drugs: what are the challenges?
    Fiona E Matthews
    MRC Biostatistics Unit, Institute of Public Health, Cambridge, UK
    Int J Geriatr Psychiatry 22:627-31. 2007
    ..Since then the cost of prescription in England and Wales has risen. There has been little investigation of uptake at the population level...
  4. ncbi Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase
    Anthony L Albiston
    Howard Florey Institute, University of Melbourne, Parkville, VIC 3010, Australia
    FASEB J 22:4209-17. 2008
    ..Notably, this study also provides unequivocal proof of principal that inhibition of IRAP results in memory enhancement...
  5. ncbi Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany
    A G Franke
    Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany
    Pharmacopsychiatry 44:60-6. 2011
    ..The aim of this study was to assess for the first time the prevalence and factors associated with stimulant use exclusively for cognitive enhancement among pupils and university students in Germany...
  6. ncbi Use of coffee, caffeinated drinks and caffeine tablets for cognitive enhancement in pupils and students in Germany
    A G Franke
    Department of Psychiatry and Psychotherapy, University Medical Centre Mainz, Mainz, Germany
    Pharmacopsychiatry 44:331-8. 2011
    ..There are only few data about substances, prevalence rates and factors associated with CE. The aim of this study was to assess first data about the use of coffee, caffeinated drinks and caffeine tablets for CE at school and university...
  7. ncbi Dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory memory tasks in mice
    Julie Vignisse
    School for Mental Health and Neuroscience, Department of Neuroscience, Maastricht University, Universiteitssingel 50, NL 6229 ER Maastricht, The Netherlands
    Prog Neuropsychopharmacol Biol Psychiatry 35:510-22. 2011
    ..Acute treatment of water-deprived and non-water-deprived mice with dimebon also did not affect their water intake. Our data suggest that dimebon enhances hippocampus-dependent learning in both appetitive and inhibitory tasks in mice...
  8. pmc Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity
    Daniel M Fass
    Center for Human Genetic Research, Massachusetts General Hospital, Department of Neurology, Harvard Medical School, 185 Cambridge Street, Boston, MA 02114, USA
    Neuropharmacology 64:81-96. 2013
    ..This article is part of a Special Issue entitled 'Cognitive Enhancers'...
  9. ncbi Citicoline in vascular cognitive impairment and vascular dementia after stroke
    Jose Alvarez-Sabin
    Neurovascular Unit, Department of Neurology, Universitat Autonoma de Barcelona, Hospital Vall d Hebron, Barcelona, Spain
    Stroke 42:S40-3. 2011
    ....
  10. ncbi Neuroprotection and recovery: recent data at the bench on citicoline
    Olivia Hurtado
    Unidad de Investigación Neurovascular, Departamento de Farmacologia, Facultad de Medicina, Universidad Complutense, Avda Complutense s n, 28040 Madrid, Spain
    Stroke 42:S33-5. 2011
    ..Furthermore, citicoline stimulates neuronal plasticity and improves sensorimotor recovery in the chronic phase of experimental stroke...
  11. ncbi Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
    Alistair Burns
    University of Manchester, Manchester, UK
    Lancet Neurol 8:39-47. 2009
    ..The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer's disease (AD). Here we report its efficacy in patients with severe AD...
  12. ncbi The use of methylphenidate among students: the future of enhancement?
    Simon M Outram
    Novel Tech Ethics, Dalhousie University, 1234 LeMarchant Street, Halifax NS B3H 3P7, Canada
    J Med Ethics 36:198-202. 2010
    ..In light of these empirically based conclusions, the article discusses why methylphenidate might have become seen as a smart drug or cognitive enhancer...
  13. ncbi "Doctor, would you prescribe a pill to help me … ?" a national survey of physicians on using medicine for human enhancement
    Timothy D Hotze
    The Institute for Ethics, Chicago, IL 60610, USA
    Am J Bioeth 11:3-13. 2011
    ..These apparently contradictory views might reflect inherent tensions between the values of equity and liberty, which could make crafting coherent social policies on medical enhancements challenging...
  14. pmc Retrospective and observational study to assess the efficacy of citicoline in elderly patients suffering from stupor related to complex geriatric syndrome
    Salvatore Putignano
    Associazione Geriatri Extraospedalieri Geriatria Italiana Territoriale, Tenore 17, Naples, Italy
    Clin Interv Aging 7:113-8. 2012
    ..We have evaluated the administration of citicoline in geriatric patients following a protocol of intravenous study on improvement of individual performances...
  15. ncbi Vitamin E and donepezil for the treatment of mild cognitive impairment
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    N Engl J Med 352:2379-88. 2005
    ..Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease...
  16. ncbi Phosphodiesterase inhibitors for cognitive enhancement
    Gregory M Rose
    Memory Pharmaceuticals Corp, 100 Philips Parkway, Montvale, NJ 07645, USA
    Curr Pharm Des 11:3329-34. 2005
    ....
  17. ncbi Pravastatin and cognitive function in the elderly. Results of the PROSPER study
    Stella Trompet
    Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
    J Neurol 257:85-90. 2010
    ..05). Pravastatin treatment in old age did not affect cognitive decline during a 3 year follow-up period. Employing statin therapy in the elderly in an attempt to prevent cognitive decline therefore seems to be futile...
  18. ncbi Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting
    Asa K Wallin
    Clinical Memory Research Unit, Department of Clinical Sciences, Malmo, Lund University, Malmo, Sweden
    Dement Geriatr Cogn Disord 23:150-60. 2007
    ..Clinical short-term trails have shown positive effects of donepezil treatment in patients with Alzheimer's disease. The outcome of continuous long-term treatment in the routine clinical settings remains to be investigated...
  19. ncbi Neuroethical issues in cognitive enhancement
    Barbara J Sahakian
    Department of Psychiatry, University of Cambridge School of Clinical Medicine, Addenbrooke s Hospital, Cambridge, UK
    J Psychopharmacol 25:197-204. 2011
    ..The present paper reviews some of the evidence in both neuropsychiatric and healthy individuals and discusses the implications such research can have for society...
  20. ncbi From anti-allergic to anti-Alzheimer's: Molecular pharmacology of Dimebon
    I Okun
    Avineuro Pharmaceuticlas Inc, San Diego, CA 92121, USA
    Curr Alzheimer Res 7:97-112. 2010
    ..Understanding the role that different pathways play in diseases with complex etiologies may allow for the rational design of multi-target drugs...
  21. ncbi Enhancing concentration, mood and memory in healthy individuals: an empirical study of attitudes among general practitioners and the general population
    Lena Strand Bergström
    Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden
    Scand J Public Health 36:532-7. 2008
    ..To study attitudes towards enhancing concentration, mood and memory in healthy individuals among the general public and general practitioners (GPs)...
  22. ncbi Effect of oral CDP-choline on plasma choline and uridine levels in humans
    R J Wurtman
    Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
    Biochem Pharmacol 60:989-92. 2000
    ..Hence, it seems likely that the circulating substrates through which oral citicoline increases membrane phosphatide synthesis in the brains of humans involve uridine and choline, and not cytidine and choline as in rats...
  23. ncbi Dietary cytidine (5')-diphosphocholine supplementation protects against development of memory deficits in aging rats
    Lisa A Teather
    Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, 45 Carleton Street, E25 604, Cambridge, MA, USA
    Prog Neuropsychopharmacol Biol Psychiatry 27:711-7. 2003
    ..These findings suggest that early-aged rats display a selective impairment in hippocampal-dependent long-term memory, and that dietary CDP-choline supplementation can protect against this deficit...
  24. pmc Dietary CDP-choline supplementation prevents memory impairment caused by impoverished environmental conditions in rats
    Lisa A Teather
    Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
    Learn Mem 12:39-43. 2005
    ....
  25. ncbi Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission
    Margarita A Morozova
    Laboratory of Psychopharmacology, Mental Health Research Center of Russian Academy of Medical Sciences, Kashirskoe Shosse 34, 115522 Moscow, Russia
    Psychiatr Danub 24:159-66. 2012
    ..A phase II study of dimebon as add-on to risperidone therapy was conducted...
  26. ncbi Neurocognitive enhancement: what can we do and what should we do?
    Martha J Farah
    Center for Cognitive Neuroscience, University of Pennsylvania, 3720 Walnut Street, Philadelphia, Pennsylvania 19104, USA
    Nat Rev Neurosci 5:421-5. 2004
  27. ncbi Probably role of citicoline in stroke rehabilitation: review of the literature
    Julio J Secades
    Medical Department, Grupo Ferrer, S A, 08028 Barcelona, Espana
    Rev Neurol 54:173-9. 2012
    ..In this context, the role of citicoline in the rehabilitation of patients with stroke is reviewed...
  28. ncbi Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion
    X A Alvarez
    EuroEspes Biomedical Research Center, A Coruna, Barcelona, Spain
    Methods Find Exp Clin Pharmacol 21:633-44. 1999
    ....
  29. ncbi Objective and subjective cognitive enhancing effects of mixed amphetamine salts in healthy people
    Irena Ilieva
    University of Pennsylvania, PA, USA
    Neuropharmacology 64:496-505. 2013
    ..We conclude that MAS has no more than small effects on cognition in healthy young adults, although users may perceive the drug as enhancing their cognition. This article is part of a Special Issue entitled 'Cognitive Enhancers'...
  30. pmc The citicoline brain injury treatment (COBRIT) trial: design and methods
    Ross Zafonte
    Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Neurotrauma 26:2207-16. 2009
    ..Secondary outcomes include survival, toxicity, and rate of recovery...
  31. ncbi Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students
    Pavel Dietz
    Department of Sports Medicine, Rehabilitation and Disease Prevention, Johannes Gutenberg University, Mainz, Germany
    Pharmacotherapy 33:44-50. 2013
    ..To estimate the 12-month prevalence of cognitive-enhancing drug use...
  32. pmc What users think about the differences between caffeine and illicit/prescription stimulants for cognitive enhancement
    Andreas G Franke
    Department of Psychiatry and Psychotherapy, University Medical Centre, Mainz, Germany
    PLoS ONE 7:e40047. 2012
    ..This result shows the need for well-directed and differentiated information to prevent the potentially harmful use of illicit or prescription stimulants for CE...
  33. ncbi The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease
    Sarah Thompson
    Sunnybrook and Women s College Health Sciences Centre, Department of Psychiatry, Rm FG 05, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada
    Expert Opin Drug Saf 3:425-40. 2004
    ..Further study is needed to examine other indications for ChEIs, as well as their combination with newer treatments, such as memantine...
  34. ncbi Use of cognitive enhancement medication among northern Italian university students
    Silvana Castaldi
    University of Milan, Fondazione IRCCS Ca Granda Ospedale Maggiore di Milano, Italy
    J Addict Med 6:112-7. 2012
    ..Students who think that there is no or an acceptable risk involved in cognitive enhancement medication are more likely to take drugs and dietary supplements than those who perceive the risk as high...
  35. ncbi Cognition and function in Alzheimer's disease: identifying the transitions from moderate to severe disease
    Elias Schwam
    Pfizer Global Pharmaceuticals, Pfizer Inc, New York, NY, USA schwae pfizer com
    Dement Geriatr Cogn Disord 29:309-16. 2010
    ....
  36. pmc Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia
    Christine E Marx
    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27705, USA
    Neuropsychopharmacology 34:1885-903. 2009
    ..Mean BACS and MCCB composite scores were correlated (r(s)=0.74, p<0.0001). Pregnenolone may be a promising therapeutic agent for negative symptoms and merits further investigation for cognitive symptoms in schizophrenia...
  37. ncbi Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial
    Pierre N Tariot
    Department of Psychiatry, University of Rochester Medical Center, Monroe Community Hospital, Rochester, NY 14620, USA
    JAMA 291:317-24. 2004
    ....
  38. pmc The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
    Robert W Buchanan
    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
    Schizophr Bull 37:1209-17. 2011
    ....
  39. ncbi Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis
    Vesna Jelic
    Division of Geriatric Medicine, Department of NVS, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Dement Geriatr Cogn Disord 26:458-66. 2008
    ..Our objective was to define clinically meaningful outcomes in donepezil versus placebo treatment in severe Alzheimer's disease (AD) and to describe characteristics of responders...
  40. ncbi Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology
    V Cakic
    University of Sydney, Australia
    J Med Ethics 35:611-5. 2009
    ..Finally, whether the prohibition of nootropics can be effectively enforced is doubtful. As nootropics use becomes widespread among students in the future, discussion of this issue will become more pressing in the years to come...
  41. ncbi A focus group on cognition-enhancing medications in Alzheimer disease: disparities between professionals and consumers
    S G Post
    Center for Biomedical Ethics, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4976, USA
    Alzheimer Dis Assoc Disord 15:80-8. 2001
    ..We also detected, as hypothesized, considerable disparity between the perspectives of professionals and consumers regarding the benefits of therapy...
  42. ncbi Efficacy of citicoline as an acute stroke treatment
    Wayne M Clark
    Department of Neurology CR131, Oregon Health Sciences University, Oregon Stroke Center, Portland, OR97201, USA
    Expert Opin Pharmacother 10:839-46. 2009
    ..Citicoline clinical efficacy trials are now continuing outside of the US in both ischemic and hemorrhagic stroke. A citicoline supplement is now available from several sources on the internet...
  43. ncbi Cognitive deficits in rats after forebrain cholinergic depletion are reversed by a novel NO mimetic nitrate ester
    Brian M Bennett
    Department of Pharmacology and Toxicology, Queen s University, Kingston, ON, Canada
    Neuropsychopharmacology 32:505-13. 2007
    ..This approach may be superior to that of current drugs that attempt only to salvage the residual function of damaged cholinergic neurons...
  44. ncbi Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease
    A Maelicke
    Laboratory of Molecular Neurobiology, Institute of Physiological Chemistry and Pathobiochemistry, Johannes-Gutenberg University Medical School, Mainz, Germany
    Biol Psychiatry 49:279-88. 2001
    ....
  45. ncbi Citicoline treatment for experimental intracerebral hemorrhage in mice
    W Clark
    Oregon Stroke Center, Oregon Health Sciences University, Portland, Oregon 97201
    Stroke 29:2136-40. 1998
    ..The present study was designed to test whether treatment with citicoline reduces ischemic injury and improves functional neurological outcome in an experimental model of ICH...
  46. ncbi Ginkgo biloba in Alzheimer's disease: a systematic review
    Inger M Janssen
    Institute for Quality and Efficiency in Health Care IQWiG, Cologne, Germany
    Wien Med Wochenschr 160:539-46. 2010
    ..A harm of Ginkgo is not evident. An estimation of the effect size was not possible for any outcome. Further evidence is needed which focuses especially on subgroups of AD patients...
  47. pmc Collaborative effects of diet and exercise on cognitive enhancement
    Fernando Gomez-Pinilla
    Department of Integrative Biology and Physiology, University of California Los Angeles, Los Angeles, CA 90095, USA
    Nutr Health 20:165-9. 2011
    ..Omega 3 fatty acids and curcumin elevate levels of molecules important for synaptic plasticity such as brain-derived neurotrophic factor (BDNF), thus benefiting normal brain function and recovery events following brain insults...
  48. ncbi Investigation into the efficacy of the acetylcholinesterase inhibitor, donepezil, and novel procognitive agents to induce gamma oscillations in rat hippocampal slices
    J P Spencer
    Synaptic Plasticity and Neural Network Dynamics Discovery Performance Unit, Neurosciences CEDD, GlaxoSmithKline, New Frontiers Science Park, Harlow, Essex, CM19 5AW, UK
    Neuropharmacology 59:437-43. 2010
    ..These data support the notion that it should be possible to find a more efficacious AChE inhibitor or an adjunctive approach, to provide a better therapeutic intervention in AD...
  49. pmc Responding to requests from adult patients for neuroenhancements: guidance of the Ethics, Law and Humanities Committee
    Dan Larriviere
    Department of Neurology and School of Law, University of Virginia, Charlottesville, VA 22908, USA
    Neurology 73:1406-12. 2009
    ....
  50. pmc Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents
    Isaac T Schiefer
    Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, MC 781, 833 South Wood Street, Chicago, Illinois 60612 7231, USA
    J Med Chem 55:3076-87. 2012
    ..The novel observation of furoxan activity of potential therapeutic use in the CNS warrants further studies...
  51. ncbi Expectations regarding cognitive enhancement create substantial challenges
    E Racine
    Neuroethics Research Unit, Institut de Recherches Cliniques de Montreal, Department of Medicine, Universite de Montreal, and Department of Neurology and Neurosurgery and Biomedical Ethics Unit, McGill University, Montreal, Canada
    J Med Ethics 35:469-70. 2009
    ....
  52. ncbi Better evidence for safety and efficacy is needed before neurologists prescribe drugs for neuroenhancement to healthy people
    Brendon P Boot
    Department of Neurology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Neurocase 18:181-4. 2012
    ..The adoption of these guidelines by neurologists could have adverse social and medical effects that need to be more carefully considered...
  53. ncbi Citicoline, use in cognitive decline: vascular and degenerative
    Rocío García-Cobos
    Department of Neurology, Stroke Center and Cognitive Impairment Unit, La Paz University Hospital, IdiPAZ Health Research Institute, Universidad Autonoma de Madrid, Madrid, Spain
    J Neurol Sci 299:188-92. 2010
    ..The use of new neuroimaging procedures in current trials could be of great interest...
  54. ncbi Verbal repetition in patients with Alzheimer's disease who receive donepezil
    Elissa Asp
    Geriatric Medicine Research Unit, Dalhousie University, Halifax, NS, Canada
    Int J Geriatr Psychiatry 21:426-31. 2006
    ..Current outcome measures for Alzheimer's disease (AD) drugs have been criticized as insufficiently patient-centred. One commonly unmeasured goal of patients and caregivers is verbal repetition...
  55. ncbi Vasodilators and nootropics as predictors of dementia and mortality in the PAQUID cohort
    Jean Francois Dartigues
    INSERM U 593, Universite de Bordeaux 2, Bordeaux, France
    J Am Geriatr Soc 55:395-9. 2007
    ..To assess the effects of treatment for memory impairment and the Ginkgo biloba extract (EGb 761) on dementia, mortality, and survival without dementia...
  56. pmc Differences in medication use in the Alzheimer's disease neuroimaging initiative: analysis of baseline characteristics
    Noam U Epstein
    Indiana University School of Medicine, Indianapolis, 46202, USA
    Drugs Aging 27:677-86. 2010
    ..Many participants in the ADNI are being treated with medications, and these may have beneficial or deleterious effects...
  57. ncbi Investigation of responders and non-responders to long-term donepezil treatment
    Jun Inoue
    Department of Psychiatry and Neurology, Hamamatsu University School of Medicine, Hamamatsu, Japan
    Psychogeriatrics 10:53-61. 2010
    ..However, not all patients respond to donepezil. In the present study, we examined the clinical features of responders and non-responders to long-term donepezil treatment...
  58. ncbi Impact of donepezil hydrochloride on the care burden of family caregivers of patients with Alzheimer's disease
    Mamoru Hashimoto
    Department of Psychiatry and Neuropathobiology, Faculty of Medical and Pharmaceutical Sciences, Kumamoto University, Honjo, Kumamoto, Japan
    Psychogeriatrics 9:196-203. 2009
    ....
  59. ncbi The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers
    Delia C Randall
    Psychopharmacology Research Unit, Centre for Neuroscience Research, King s College London, London, UK
    Pharmacol Biochem Behav 77:547-55. 2004
    ..Thus, this study found limited evidence of cognitive-enhancing properties of modafinil in healthy middle-aged volunteers...
  60. ncbi Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine
    Roger Bullock
    Kingshill Research Centre, Victoria Hospital, Swindon, UK
    Dement Geriatr Cogn Disord 17:29-34. 2004
    ..Subgroup analysis was performed of patients with AD + CVD who participated in a 6-month, multicenter, randomized, double-blind, parallel-group study and a 6-month, open-label, active-treatment extension...
  61. ncbi Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors
    V Suppiramaniam
    Department of Biology, Tuskegee University, Tuskegee, Alabama, USA
    Synapse 40:154-8. 2001
    ..They also raise the possibility that AMPA receptors are regulated by factors present in situ, thus explaining the more efficient modulatory effects of CX509 when acting on receptors removed from their synaptic location...
  62. ncbi Effects of donepezil on activities of daily living: integrated analysis of patient data from studies in mild, moderate and severe Alzheimer's disease
    Serge Gauthier
    McGill Center for Studies in Aging, Douglas Mental Health University Institute, Douglas Hospital, Verdun, QC, Canada
    Int Psychogeriatr 22:973-83. 2010
    ....
  63. ncbi Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation?
    Lucilla Parnetti
    Clinica Neurologica, Dipartimento di Specialità Medico Chirurgiche e Sanità Pubblica, Universita di Perugia, Perugia, Italy
    J Neurol Sci 257:264-9. 2007
    ..However, they probably would justify reconsideration of the most promising molecules in larger carefully controlled studies...
  64. ncbi Mitochondria as a target for neurotoxins and neuroprotective agents
    Sergey O Bachurin
    Institute of Physiologically Active Compounds, Chernogolovka, Russia
    Ann N Y Acad Sci 993:334-44; discussion 345-9. 2003
    ..Substances that may prevent opening of mitochondrial pores induced by neurotoxins may preserve the mitochondrial function and, thus, may have potential as neuroprotective agents...
  65. ncbi Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study
    Mercè Boada-Rovira
    Fundacio ACE, Barcelona, Spain
    Drugs Aging 21:43-53. 2004
    ..However, in order to control for confounding factors, some clinical trials of donepezil have excluded patients with comorbid illness and concomitant medication use...
  66. ncbi Donepezil in vascular dementia: a randomized, placebo-controlled study
    D Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Neurology 61:479-86. 2003
    ..To evaluate the efficacy and tolerability of donepezil in patients with vascular dementia (VaD)...
  67. ncbi Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons
    X Zhao
    Department of Molecular Pharmacology and Biological Chemistry, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Mol Pharmacol 59:674-83. 2001
    ..Although nefiracetam and aniracetam inhibited alpha 7-type currents only weakly, these nootropic agents potentiated alpha 4 beta 2-type currents in a very potent and efficacious manner...
  68. pmc DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT
    Rob Jones
    Section of Old Age Psychiatry, The University of Nottingham, A Floor, South Block, Queen s Medical Centre, Nottingham NG7 2UH, UK
    Trials 10:57. 2009
    ..The aim of this trial is to establish the most effective drug option for people with AD who are progressing from moderate to severe dementia despite treatment with donepezil...
  69. ncbi Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study
    Julio J Secades
    Medical Department, Grupo Ferrer SA, Barcelona, Spain
    Cerebrovasc Dis 21:380-5. 2006
    ..Citicoline is a neuroprotectant drug with some beneficial effects in human ischaemic stroke and with an excellent safety profile. We decided to carry out a pilot study to test its safety and efficacy in human intracerebral haemorrhaging...
  70. ncbi Neuroprotective and antiamnesic effect of donepezil, a nicotinic acetylcholine-receptor activator, on rats with concussive mild traumatic brain injury
    Minoru Fujiki
    Department of Neurosurgery, School of Medicine, Oita University, Oita, Japan
    J Clin Neurosci 15:791-6. 2008
    ..However, these neuroprotective effects were prevented by concomitant injection of mecamylamine, a nicotinic acetylcholine-receptor (nAChR) antagonist, indicating that protection is mediated by nAChR activation...
  71. ncbi [Donepezil-induced neuroprotection of acetylcholinergic neurons in olfactory bulbectomized mice]
    Yui Yamamoto
    Department of Pharmacology, Tohoku University, Sendai, Japan
    Yakugaku Zasshi 130:717-21. 2010
    ..We will also discuss the mechanism underlying the donepezil-induced neuroprotection in the medial septum cholinergic neurons...
  72. ncbi Can we do better in developing new drugs for Alzheimer's disease?
    Serge Gauthier
    Department of Psychiatry, Neurology and Neurosurgery, McGill Center for Studies in Aging, McGill University, Montreal, Quebec, Canada
    Alzheimers Dement 5:489-91. 2009
    ....
  73. ncbi Donepezil in the treatment of patients with Alzheimer's disease
    Norifumi Tsuno
    Department of Psychiatry, Tokyo Jikei University School of Medicine, Tokyo, Japan
    Expert Rev Neurother 9:591-8. 2009
    ....
  74. pmc A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline
    H H Dodge
    Department of Public Health, Oregon State University, Corvallis, OR 97401, USA
    Neurology 70:1809-17. 2008
    ..To assess the feasibility, safety, and efficacy of Ginkgo biloba extract (GBE) on delaying the progression to cognitive impairment in normal elderly aged 85 and older...
  75. ncbi Tacrine-induced liver damage: an analysis of 19 candidate genes
    Ana Alfirevic
    Department of Pharmacology and Therapeutics, The University of Liverpool, Sherrington Building, Ashton Street, Liverpool, UK
    Pharmacogenet Genomics 17:1091-100. 2007
    ..Our aim was to investigate whether single-nucleotide polymorphisms (SNPs) in 19 candidate genes were associated with tacrine-induced liver damage...
  76. ncbi Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
    A Burns
    University of Manchster, Manchester, UK
    Int J Geriatr Psychiatry 22:806-12. 2007
    ....
  77. ncbi Nootropic agents stimulate neurogenesis. Brain Cells, Inc.: WO2007104035
    Philippe Taupin
    Dublin City University, School of Biotechnology, Glasnevin, Dublin 9, Ireland
    Expert Opin Ther Pat 19:727-30. 2009
    ..It aims to characterize the activity of nootropic agents on adult neurogenesis in vitro. Nootropic agents are substances improving cognitive and mental abilities...
  78. ncbi Pharmacological discrimination of extinction and reconsolidation of contextual fear memory by a potentiator of AMPA receptors
    Daisuke Yamada
    Department of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, Japan
    Neuropsychopharmacology 34:2574-84. 2009
    ..PEPA and DCS did not affect reextinction. These results suggest that PEPA acts on extinction of contextual fear memory without having detectable influences on its reconsolidation...
  79. ncbi Forgetting and remembering. A star-studded search for memory-enhancing drugs
    Eliot Marshall
    Science 304:36-8. 2004
  80. ncbi Dementia with cerebrovascular disease: the benefits of early treatment
    R J Schindler
    Pfizer Inc, 235 East 42nd Street, New York, NY 10017 5775, USA
    Eur J Neurol 12:17-21. 2005
    ..The results of these studies support the use of donepezil in treatment of patients with VaD or AD + CVD...
  81. ncbi Effects of prenatal nicotine exposure on primate brain development and attempted amelioration with supplemental choline or vitamin C: neurotransmitter receptors, cell signaling and cell development biomarkers in fetal brain regions of rhesus monkeys
    Theodore A Slotkin
    Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC 27710, USA
    Neuropsychopharmacology 30:129-44. 2005
    ....
  82. ncbi Cosmetic neurology: the controversy over enhancing movement, mentation, and mood
    Anjan Chatterjee
    Department of Neurology and the Center for Cognitive Neuroscience, The University of Pennsylvania, 3 West Gates, 3400 Spruce St, Philadelphia, PA 19104, USA
    Neurology 63:968-74. 2004
    ..Neurologists and other clinicians are likely to encounter patient-consumers who view physicians as gatekeepers in their own pursuit of happiness...
  83. pmc Dietary choline supplementation improves behavioral, histological, and neurochemical outcomes in a rat model of traumatic brain injury
    Maria V Guseva
    Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536 0082, USA
    J Neurotrauma 25:975-83. 2008
    ..The results of this study suggest that alpha7 nAChR agonists may be useful drugs to enhance recovery following brain injury...
  84. pmc The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial
    Kenneth Rockwood
    Division of Geriatric Medicine, Department of Medicine, Dalhousie University, Halifax, Canada
    BMC Neurol 7:26. 2007
    ..We examined how this change compared with measures of clinical meaningfulness...
  85. ncbi Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE < or = 12) for up to six months
    D G Wilkinson
    Memory Assessment and Research Centre, Moorgreen Hospital, Southampton, UK
    Int J Clin Pract 56:509-14. 2002
    ..5 ADAS-cog points. Cognitive and functional abilities were maintained around baseline; behavioural symptoms were delayed. Over 6 months, galantamine provided a broad spectrum of benefits to patients with 'advanced moderate' AD...
  86. ncbi The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease
    C Holmes
    Memory Assessment and Research Centre, University of Southampton, Clinical Neurosciences Research Division, Moorgreen Hospital, Botley Rd, Southampton, UK
    Neurology 63:214-9. 2004
    ..To determine the efficacy of donepezil in the treatment of neuropsychiatric symptoms in patients with Alzheimer disease (AD) in a randomized withdrawal study...
  87. ncbi 'Smart drugs': do they work? Are they ethical? Will they be legal?
    Steven P R Rose
    Brain and Behaviour Research Group at The Open University, Milton Keynes MK7 6AA, UK
    Nat Rev Neurosci 3:975-9. 2002
  88. pmc Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group
    G K Wilcock
    Department of Care of the Elderly, Frenchay Hospital, University of Bristol, Bristol BS16 1LE
    BMJ 321:1445-9. 2000
    ..To evaluate the efficacy and safety of galantamine in the treatment of Alzheimer's disease...
  89. ncbi Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic
    H P Matthews
    Southampton Memory Clinic, Moorgreen Hospital, Southampton SO30 3JB, UK
    Int J Geriatr Psychiatry 15:713-20. 2000
    ..Continued benefit was seen for up to 18 months in the selected group of patients who initially responded in treatment...
  90. ncbi How many patients complete an adequate trial of donepezil?
    Catherine M Roe
    Outcomes Research, Express Scripts, Inc, Maryland Heights, Missouri, 3043, USA
    Alzheimer Dis Assoc Disord 16:49-51. 2002
    ..627 +/-.124. Additionally, 13.9% of those who continued therapy for at least 180 days showed gaps in treatment of six weeks or more. These results suggest that adherence with donepezil could be improved in clinical practice...
  91. ncbi Regulation of neuronal function by choline and 4OH-GTS-21 through alpha 7 nicotinic receptors
    Vladimir V Uteshev
    Department of Pharmacology and Therapeutics, University of Florida College of Medicine, University of Florida, Gainesville, Florida 32610 0267, USA
    J Neurophysiol 89:1797-806. 2003
    ....
  92. ncbi Treatment of vascular dementia: evidence from trials with non-cholinergic drugs
    Leonardo Pantoni
    Azienda Ospedaliera Careggi and University of Florence, Florence, Italy
    J Neurol Sci 226:67-70. 2004
    ..This selective focus seems to be better suited for disclosing specific treatments in the field of VaD...
  93. ncbi CDP-choline, but not cytidine, protects hippocampal CA1 neurones in the gerbil following transient forebrain ischaemia
    P Grieb
    Laboratory of Experimental Pharmacology, Medical Research Centre, Polish Academy of Sciences, Warszawa
    Folia Neuropathol 39:141-5. 2001
    ..The choline moiety of CDP-choline appears to be essential for the neuroprotective properties of the drug...
  94. ncbi Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden
    Howard Feldman
    Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
    J Am Geriatr Soc 51:737-44. 2003
    ....
  95. ncbi [Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office]
    J Kohler
    Neurologische Universitatsklinik, Ulm
    Fortschr Med Orig 120:135-41. 2002
    ..They therefore provide the basis for a modern diagnostic work-up and treatment strategy, which will also meet economical demands...
  96. ncbi Comparative analysis of mortality in patients with Alzheimer's disease treated with donepezil and galantamine
    Dolors Capellà
    Age Ageing 36:234; author reply 235. 2007
  97. ncbi Acetylcholinesterase inhibitors for vascular dementia and Alzheimer's disease combined with cerebrovascular disease
    John V Bowler
    Department of Neurology, Royal Free Hospital, London, UK
    Stroke 34:584-6. 2003
  98. ncbi Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment
    B Seltzer
    Alzheimer s Disease and Memory Disorders Center, Department of Psychiatry and Neurology, Tulane University School of Medicine, New Orleans, LA 70112, USA
    J Int Med Res 34:339-47. 2006
    ..This article identifies barriers to early recognition and effective care of patients with Alzheimer's disease and discusses practical strategies to overcome them...
  99. ncbi [Acetylcholinesterase inhibitors for dementia--an update]
    Ion Anghelescu
    Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charite Berlin
    MMW Fortschr Med 149:76-8. 2007
    ..The three substances differ in their efficacy and their pharmacological properties. AChE inhibitors should be used for long-term treatment. The clinical course should be monitored every six months...
  100. ncbi Efficacy of cognitive rehabilitation in patients with mild cognitive impairment treated with cholinesterase inhibitors
    Luca Rozzini
    Department of Neurology, University of Brescia, Italy
    Int J Geriatr Psychiatry 22:356-60. 2007
    ..The high rate of conversion from MCI to AD makes early treatment an important clinical issue. Recent evidence suggests that cognitive training intervention may reduce the rate of progression to AD...
  101. ncbi [Medical treatment of Alzheimer's disease]
    Peter Johannsen
    H S Hukommelsesklinikken, Neurologisk Klinik, H S Rigshospitalet, København Ø
    Ugeskr Laeger 168:3424-9. 2006
    ..The life expectancy does not seem to be altered. There is documented effect on the cholinesterase inhibitors of up to two years and for memantine for 6 months. New disease modifying agents are under clinical development...

Research Grants71

  1. HIPPOCAMPAL FUNCTION DURING CORTICOSTEROID THERAPY
    E Sherwood Brown; Fiscal Year: 2004
    ..Through this award, the Pl will extend his previous research experience by adding new skills and knowledge which will be used for investigations at the interface of neuroscience and clinical research. ..
  2. Evaluation of Antioxidant Suppl in Focal CNS Ischemia
    Wayne Clark; Fiscal Year: 2003
    ..The information obtained from this project will be critical in planning future clinical stroke trials involving these agents. ..
  3. Cocaine Withdrawal and Pharmacotherapy Response
    Mehmet Sofuoglu; Fiscal Year: 2010
    ..This proposal, by testing the efficacy of carvedilol and investigating the influence of withdrawal severity on carvedilol's efficacy, may result in development of more effective treatments for cocaine addiction. ..
  4. Progestrone and the Effects of Nicotine
    Mehmet Sofuoglu; Fiscal Year: 2006
    ..By characterizing the progesterone effects on nicotine dependence, this study may provide a better understanding of the mechanisms which mediate the sex and menstrual cycle phase effects on nicotine dependence. ..
  5. GABA Medications for Tobacco Addiction
    Mehmet Sofuoglu; Fiscal Year: 2009
    ..The findings of this study will provide valuable information to develop new pharmacotherapies for smoking cessation. ..
  6. Kinase Inhibitors against Neurodegeneration
    Gary Lynch; Fiscal Year: 2004
    ....
  7. Treating Asthma Patients with Major Depressive Disorder
    E Sherwood Brown; Fiscal Year: 2004
    ....
  8. Integrin and LTP Consolidation
    Gary Lynch; Fiscal Year: 2003
    ..abstract_text> ..
  9. Diethanolamine, brain development and adult memory
    Steven Zeisel; Fiscal Year: 2006
    ..abstract_text> ..
  10. Naltrexone for Bipolar Disorder and Alcohol Dependence
    E Sherwood Brown; Fiscal Year: 2006
    ..Alcohol use is the primary outcome, and alcohol craving is the secondary outcome. Manic and depressive symptom severity and the relationship between changes in alcohol use and changes in mood will be expIored. ..
  11. NUTRITIONAL BIOCHEMISTRY AND EPIDEMIOLOGY OF CANCER
    Steven Zeisel; Fiscal Year: 2006
    ..We are requesting two postdoctoral and six predoctoral trainee positions each year for this purpose. ..
  12. Integrins and LTP consolidation
    Gary Lynch; Fiscal Year: 2008
    ..The results of these experiments are expected to provide a strong test of a specific hypothesis regarding how LTP, and therefore possibly memory, becomes consolidated. ..
  13. CDP-choline: Mechanisms in Cerebral Ischemia
    RAO ADIBHATLA; Fiscal Year: 2006
    ..Arachidonic acid activates neutral sphingomyelinase, resulting in membrane disintegration. PCCT activity was stimulated by exogenous CDP-choline. Aim 2 will be tested in gerbil transient forebrain ischemia. ..
  14. Pilot Study of Huperzine A in Alzheimer's Disease
    Paul Aisen; Fiscal Year: 2003
    ....
  15. Alzheimer's Disease Prevention Trial with Estrogens
    Mary Sano; Fiscal Year: 2007
    ..This trial may represent the very last chance to determine if estrogen can have a benefit in dementia prevention and memory protection. ..
  16. RSA Lecture Series
    Jennifer Thomas; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  17. Pharmacotherapy for Minor Depression
    Robert Howland; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  18. Geriatric Depression: Getting Better, Getting Well
    Charles Reynolds; Fiscal Year: 2008
    ..This is an amended (A2) competing continuation of (MH37869-21). ..
  19. Institute for Research Minority Training on Mental Health
    Jacobo Mintzer; Fiscal Year: 2007
    ..We expect this effort to be the incubator for a new generation of minority researchers dedicated to the study mental health and aging. ..
  20. NEUROGENETICS AND BEHAVIOR CENTER
    Michela Gallagher; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  21. Predictors of Alzheimers Disease in Mild Cognitive Impairment
    Oscar Lopez; Fiscal Year: 2007
    ..g., structural and perfusion MRI, plasma beta-amyloid) and the factors that modify the risk to express the clinical syndrome takes on an added importance. [unreadable] [unreadable] [unreadable] [unreadable]..
  22. Improving memory after hippocampal cell loss
    MARK BARDGETT; Fiscal Year: 2007
    ..The results may shed light on new directions in the treatment of memory disorders, and the proposed work will also enhance education in biomedical research among college undergraduates in Kentucky. [unreadable] [unreadable] [unreadable]..
  23. Comorbid Substance Abuse and Long-Term Health Outcomes in Schizophrenia
    DEANNA KELLY; Fiscal Year: 2008
    ..This will be an important step for improving the lives of people with schizophrenia. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]..
  24. Neurobiology of Dopamine in Schizophrenia
    Jeffrey Lieberman; Fiscal Year: 2008
    ..abstract_text> ..
  25. D-Cycloserine Enhancement of Exposure in Social Phobia
    Mark H Pollack; Fiscal Year: 2010
    ..This study addresses an important public health issue by assessing an intervention that may lead to a more efficient and effective application of empirically based psychosocial interventions for the treatment of SAD. ..
  26. Comparative Effectiveness Study for Bipolar Disorder
    Andrew A Nierenberg; Fiscal Year: 2010
    ..The two treatments will be the second generation antipsychotic mood stabilizer quetiapine and the classic mood stabilizer lithium. In addition to quetiapine or lithium, participants can be treated with other medications as needed. ..
  27. Effects of Chemotherapy on Brain Function
    William J Jagust; Fiscal Year: 2010
    ..They are also relevant to the overall mission of the NIH because of the negative impact that cognitive dysfunction has on quality of life. ..
  28. Juvenile Bipolar Disorder and Substance Abuse
    Timothy E Wilens; Fiscal Year: 2010
    ..Since BPD is identifiable and treatable, findings from the four-year follow-up will provide valuable information to formulate prevention and early intervention strategies. ..
  29. Morphine versus Methadone as First Line Strong Opioid for Cancer Pain
    Eduardo Bruera; Fiscal Year: 2009
    ..Relevance to Public Health: In this study, we will test if methadone is better than morphine in cancer pain control, quality of life, and is more cost-effective. ..
  30. Amyloid Imaging in Frontotemporal Dementia and Alzheimer's Disease
    William Jagust; Fiscal Year: 2009
    ..PIB could become a diagnostic tool that is useful in diagnosing AD and FTLD during life. This will be especially important as new treatments for both disorders are developed. ..
  31. Neonatal Ethanol-Induced Memory Impairments in Rats
    Pamela Hunt; Fiscal Year: 2009
    ..The potential for amelioration of these cognitive deficits using both behavioral and pharmacological strategies will provide important information regarding treatment approaches for afflicted individuals. ..
  32. BASAL GANGLIA OUTPUT AND PSYCHOSTIMULANT ABUSE
    Heinz Steiner; Fiscal Year: 2009
    ..This work will help establish an improved cellular framework necessary to understand and successfully treat cocaine addiction. ..
  33. Molecular and Functional Imaging of Age Related Cognitive Decline
    William Jagust; Fiscal Year: 2009
    ....
  34. Creation and demonstration of a palliative care research cooperative group
    Jean S Kutner; Fiscal Year: 2010
    ....
  35. SYNAPTIC ALTERATIONS AFTER HYPOGLYCEMIC SEIZURES
    Kelvin Yamada; Fiscal Year: 2008
    ..Understanding mechanisms of diabetes/diabetes complication-induced brain dysfunction may lead to new targets for treatment interventions to prevent or retard cognitive impairment in diabetes. ..
  36. Topiramate for alcohol and cocaine dependence
    Kyle Kampman; Fiscal Year: 2008
    ..abstract_text> ..
  37. Do Housing Conditions Influence Learning & Retention of a Working Memory Task?
    JAMES CHURCHILL; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  38. Behavior/Drug Interactions in Striatal gene Regulation
    Heinz Steiner; Fiscal Year: 2003
    ..These studies should provide new insights into how the behavior executed during the drug action can influence drug-induced neuroplasticity in the striaturn. ..
  39. DO HIGH DOSE B VITAMINS DELAY AGE-RELATED DECAY
    Bruce Ames; Fiscal Year: 2005
    ....
  40. Plasma Markers of Dietry Intervention to Delay Cognitiv*
    JAE KANG; Fiscal Year: 2005
    ..Importantly, results from the proposed grant will lay the groundwork for a future, large-scale comprehensive study to examine dietary interventions to delay cognitive function. ..
  41. Tuning-Up Human Metabolism
    Bruce Ames; Fiscal Year: 2005
    ..Previous results showed that high doses of key mitochondrial metabolites delay mitochondrial decay and involve Km. 4) Minimizing DNA damage and cancer by optimizing micronutrient levels, particularly in the elderly. ..
  42. Pharmacotherapy for Minor Depression
    Andrew Nierenberg; Fiscal Year: 2004
    ..The results of this study will have profound public health implications by improving our understanding of the efficacy of SJW and standard antidepressants for the treatment of MinorD. ..
  43. TREATMENT OF SOCIAL PHOBIA--MEDIATORS AND MODERATORS
    Stefan Hofmann; Fiscal Year: 2002
    ..The main hypothesis is that perceived emotional control will mediate treatment outcome and generality of effectiveness independent of the specific treatment condition. ..
  44. Society for the Study of Ingestive Behavior Annual Meet
    Timothy Moran; Fiscal Year: 2003
    ..abstract_text> ..
  45. DM1-Monoclonal Antibody Conjugates
    Charles Hutchinson; Fiscal Year: 2002
    ..Therefore, a successful outcome of our research would meet the needs for preclinical and clinical development at a far lower cost than the current DM1 synthesis that is the only source of this cytotoxin. ..
  46. Impact of Trauma of Terroist Attack on Bipolar Patients
    Mark Pollack; Fiscal Year: 2003
    ..abstract_text> ..
  47. PAR04-122 Satellite Animal Facility Construction Project
    Jeffrey Lieberman; Fiscal Year: 2009
    ..The design will meet all NIH guidelines for the care and use of laboratory animals and health and safety regulations for staff. ..
  48. PET, APOE & The Preclinical Course of Alzheimer Disease
    Eric Reiman; Fiscal Year: 2006
    ..abstract_text> ..
  49. Clozapine Treatment of Schizophrenic Patients
    Robert Buchanan; Fiscal Year: 2006
    ..The study will provide new information on the clinical utility of adjunctive risperidone in treatment-resistant patients who fail to adequately respond to clozapine. ..
  50. LONG TERM DRUG ABUSE IN ADHD
    Timothy Wilens; Fiscal Year: 2002
    ..abstract_text> ..
  51. Behavioral Genetics and Toxic Response
    Edward Levin; Fiscal Year: 2002
    ....
  52. ATTENTION, CORTICAL ACH RELEASE AND NEURONAL ACTIVITY
    Martin Sarter; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  53. GENETIC LINKAGE OF AUDITORY GATING
    Karen Stevens; Fiscal Year: 2001
    ..Such information could be important in understanding of the etiology of the disorder and in determining future therapeutic interventions. ..
  54. MALDI-TOF MASS SPECTROMETER
    Bruce Ames; Fiscal Year: 2002
    ..abstract_text> ..
  55. Improving Outcomes in Pharmacotherapy of Social Phobia
    Mark Pollack; Fiscal Year: 2009
    ..It thus directly addresses a critical public health issue that adversely affects a substantial proportion of the population. ..
  56. Depressoin in Alzheimer's Disease Study-2 (DIADS-2)
    Jacobo Mintzer; Fiscal Year: 2007
    ..abstract_text> ..
  57. THE FUNCTIONAL SIGNIFICANCE OF HIPPOCAMPAL SPROUTING
    Julio Ramirez; Fiscal Year: 2008
    ..The proposed project will explore whether changes in brain cell connectivity may contribute to some of the behavioral alterations that are associated with schizophrenia. [unreadable] [unreadable] [unreadable]..
  58. DELAYING MITOCHONDRIAL DECAY WITH CARNITINE AND LIPOATE
    Bruce Ames; Fiscal Year: 2001
    ..abstract_text> ..
  59. Metalloproteome of the Aging Rat Brain Mitochondria
    Bruce Ames; Fiscal Year: 2007
    ..Thus, this work has significant potential to integrate numerous aspects of mitochondrial metabolism and physiology and reveal novel opportunities for combating aging-related decline. [unreadable] [unreadable] [unreadable]..
  60. Aging and Sites of Action of Cognition-Enhancing Drugs
    DIANA WOODRUFF PAK; Fiscal Year: 2008
    ..These studies will likely support hypotheses about ACh mechanisms in learning and memory and may identify the cerebellum as an additional site of drug action. [unreadable] [unreadable]..
  61. Mechanisms of Neuronal Regeneration after Stroke in a Novel Neurovascular Niche
    STANLEY THOMAS CARMICHAEL; Fiscal Year: 2010
    ..An understanding of the molecules that promote this neural stem cell response after stroke will help develop novel therapies to promote replacement of brain cells in this disease. ..
  62. Predicting Transitions Among Community-Dwelling Elders
    Ilene Zuckerman; Fiscal Year: 2008
    ....
  63. MR SPECTROSCOPIC IMAGING DURING METHADONE MAINTENANCE
    Mark Pollack; Fiscal Year: 2002
    ....
  64. REPRESENTATION OF TEMPORAL INFORMATION
    CATALIN BUHUSI; Fiscal Year: 2009
    ..This information is crucial to assessing the value/efficiency of potential treatment strategies in animal models of such disorders. ..
  65. TARDIVE DYSKINESIA INCIDENCE AND ATYPICAL ANTIPSYCHOTIC
    Scott Woods; Fiscal Year: 2004
    ..The existence of a previous sample at the same site provides a useful additional comparison group. Methods including sample ascertainment and TD assessment are closely modeled after the original work. ..
  66. PATHOPHYSIOLOGY IN NEURODEGENERATION
    Russell Swerdlow; Fiscal Year: 2002
    ....
  67. Methylphenidate for Fatigue in Advanced Cancer Patients
    Eduardo Bruera; Fiscal Year: 2009
    ....
  68. Light Treatment for Sleep/Wake Disturbances AD
    Jerome Yesavage; Fiscal Year: 2008
    ..Outcome will be documented by objective circadian activity rhythm parameters and standard sleep/wake measures both assessed by actigraphy. ..
  69. Prevention of post-stroke depression-treatment strategy
    Robert Robinson; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  70. AGING AND DEMENTIA--LONGITUDINAL COURSE OF SUBGROUPS
    Barry Reisberg; Fiscal Year: 2002
    ..Collectively, these cohorts include over 1300 persons. The comprehensive evaluations include behavioral, mental status, neuropsychologic, neurologic, neuroimaging, electrophysiologic, and postmortem studies. ..